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Abstract
Objectives—To evaluate the reliability and factorial validity of the four-item Morisky Green 
Levine Medication Adherence Scale (MGLS) among Atherosclerosis Risk in Communities 
(ARIC) Study participants.
Methods—We used cross-sectional data from ARIC Study Visit 5 to assess the measurement 
properties of MGLS. We measured the internal consistency using Cronbach’s Alpha, where α>.70 
is considered reliable for group-level measurement, the response frequency, and inter-item 
correlation. Factor analysis of MGLS and five other adherence items in the survey was conducted 
using a polychoric correlation matrix to examine the dimensionality that underlies the MGLS. A 
vanishing tetrad test (VTT) was conducted to assess conformity with an effect indicator model.
Results—Among ARIC Visit 5 participants, 6,261 (96%) responded to the MGLS and other 
questions related to medication adherence in the survey (mean age 76±5, 59% women). The 
Cronbach’s alpha for MGLS was 0.47. The inter-item correlations ranged from 0.11 to 0.26. In the 
factor analysis of medication adherence survey questions a three-factor solution was used. One 
factor captured the extent of nonadherence while other factors focused on reasons for 
nonadherence. The MGLS items spread out across the factors that reflect the extent as well as the 
reasons of non-adherence. The VTT results indicated that MGLS consists of items other than 
effect indicators (p<0.0001).
Conclusions—The low reliability together with the factor analyses findings implies that MGLS 
may reflect causes as well as the extent of medication adherence. The findings suggest that the 
MGLS as presently used, lacks consistency in an elderly population.
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Introduction
Medication adherence, which is defined as “the extent to which a person’s behavior with 
regard to taking medication corresponds with agreed recommendations from a health care 
provider” [1] has been the subject of extensive research for the past several decades. [2,3] 
The World Health Organization (WHO) estimated that approximately 50% of patients with 
chronic diseases are adherent to their medications in developed countries. [4] Studies have 
shown that medication non-adherence is associated with worse clinical outcomes, [5,6] 
including higher hospitalization rates, [7] greater risk of preventable medication-related 
hospital admissions, [8] and a higher mortality rate. [9]
Marcum and colleagues suggested that medication non-adherence should be viewed as a 
diagnosable and treatable medical condition. [10] In this framework, treating medication 
non-adherence requires establishing an accurate assessment of adherence and determining 
the causal factors associated with adherence. However, medication non-adherence remains 
unidentified in a significant portion of patients across various healthcare settings. [10]
Different methods of measuring non-adherence exist that are applicable across various 
clinical and research settings. Direct measures such as tracing the parent medication or its 
metabolites in the body are accurate but are associated with higher cost and less applicability 
in research and clinical practice settings. Indirect methods focus on measuring medication 
adherence as a behavior and include approaches ranging from electronic medication 
monitoring and pill count to pharmacy refills and self-report measures. [11] Several 
advantages are associated with self-report measures of medication adherence, including the 
ease of implementation in different settings and the ability to identify reasons underlying the 
medication adherence behavior. Hence, self-report measures are commonly used to measure 
medication adherence. However, self-report measures of medication adherence have been 
widely criticized for their less than desirable measurement characteristics [12] and tendency 
to overestimate medication adherence by 10–20% compared to other methods. [13,14,15,16]
One of the most commonly used self-reported measure of medication non-adherence is the 
four-item Morisky Green Levine Medication Adherence Scale (MGLS). [17,18,19] 
Although MGLS is widely used for measuring the extent of medication non-adherence, 
Voils and colleagues argue that MGLS contains the items that identify respondents’ reasons 
for non-adherence. [11] Therefore, conceptually MGLS cannot be appropriately classified as 
a measure of extent of medication non-adherence (i.e., an effect indicator model) and more 
appropriately falls into the category of measures of causes of medication non-adherence 
(i.e., a causal indicator model). [11] These two models have divergent implications for 
measure validation. [11] High inter-item correlation and internal consistency are required for 
a measure in an effect indicator model, while in a causal indicator model the items ideally 
capture different and perhaps unrelated aspects of the construct. Therefore, high internal 
consistency and inter-item correlations are not expected for causal indicator models. [11] 
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Since MGLS has been commonly used as an effect indicator model, we evaluate MGLS 
within this framework to see if practical data supports the use of MGLS as a measure of the 
extent of medication adherence. This study aims to evaluate the reliability and factorial 
validity of the MGLS as a measure of medication non-adherence in an elderly cohort from 
four US communities.
Methods
Data
We use the cross-sectional Visit 5 data from the Atherosclerosis Risk in Communities 
(ARIC) Study. The ARIC Study is a prospective cohort study investigating the etiology of 
atherosclerotic disease in a middle-aged, predominantly biracial population. Details 
regarding the ARIC study have been previously published. [20] Briefly, in 1987–1989, 
15,792 men and women aged 45–64 attended the baseline clinic examination (Visit 1). 
Participants were invited to three subsequent visits at approximately three-year intervals 
followed by Visit 5 in 2011–2013. Among 10,749 participants who were eligible for Visit 5, 
706 participants died before Visit 5 was completed and 3,505 people refused or were unable 
to participate [21]. Among the remaining 6,538 participants, the data for 6,261 participants 
(96%) who completed all questions regarding medication adherence were analyzed. 
Participants who reported no medication consumption at Visit 5 were also excluded from the 
analyses. Racial composition is highly linked to geographic site in the ARIC cohort, with 
only African-Americans enrolled in Jackson, and extremely few African-Americans in the 
Minneapolis and Washington county sites or participants of other race at any site. We 
therefore included only the majority race at each site except for Forsyth County (which has a 
mix of whites and African-Americans).
Measures
In this study, we used the four-item Morisky Medication Adherence Scale (MGLS), which 
includes four questions with yes/no response options. The MGLS results in a score ranging 
from 0 to 4, and the developers suggested three levels of medication adherence based on this 
score: high, medium and low adherence with 0, 1–2, and 3–4 points, respectively. [19] A 
dichotomous definition of adherence based on MGLS is also commonly used with 0 points 
indicating perfect adherence and 1+ points indicating some level of non-adherence. [11]
In addition to MGLS, other measures of medication adherence used in the Visit 5 survey 
include: three questions asking about the frequency of non-adherence with a four-week 
recall period; a single question directly asking the percent of the time that a participant was 
fully adherent in the past four weeks; and for cohort participants who reported less than 
100% adherence in the past four weeks, self-reported reasons for medication non-adherence 
(including 11 potential reasons for non-adherence) were asked (Table 1).
Statistical Analysis
We assess the psychometric properties (reliability, and congruent and factorial validity) of 
the MGLS as an effect indicator model for measuring the extent of medication non-
adherence. All the analyses were conducted using STATA 13. College Station, TX.
Beyhaghi et al. Page 3
Value Health. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Reliability (internal consistency)—Reliability refers to the degree to which an 
instrument is free from measurement error. Internal consistency measures whether items that 
propose to measure the same general construct produce similar scores. In this study we 
conducted item analyses including response frequencies and Spearman’s inter-item 
correlations to assess the reliability of MGLS. Internal consistency was assessed using 
Cronbach’s Coefficient Alpha, where α>.70 is considered reliable for group-level 
measurement. [22].
Assessing the validity of MGLS—The magnitude of association between the MGLS 
dichotomous score and a single-item measure directly reflecting the extent of medication 
adherence (i.e. adherent 100% of the time vs. any level of non-adherence) was estimated to 
test the scale congruent validity as a measure of the extent of adherence. We selected the 
MGLS dichotomous score primarily because of the distribution of the scores i.e., only 2.3% 
of study participants had 3 or 4 points indicating low adherence.
Factor analysis was used to examine the dimensionality of the MGLS. The standard methods 
of performing factor analysis use a Pearson correlations matrix to estimate the factor 
patterns and hence assume that the variables are on a normal interval scale. Since MGLS 
items have a binary response option, we conducted a factor analysis using a polychoric 
correlation matrix to adjust for the binary nature of the data. The polychoric correlation is a 
measure of association for ordinal variables, which assumes an underlying joint continuous 
distribution. [23]
We also conducted a factor analysis of all the questions related to medication adherence in 
the survey except for the redundant items (e.g. medication not taken on time because poor 
memory) and rare items (e.g. medication not taken on time because too complicated) to 
identify how the number of underlying factors and MGLS items factor loading compare to 
other items in the survey (Table 1). To obtain a simple factor structure and improve the 
interpretability of the factors, unrotated solutions were compared to the rotated factor 
solutions. Oblique rotation (promax rotation) was used to account for the potential 
correlation of factors and improve the interpretability of the results. In order for an item to 
be considered a relevant contributor to a factor, the factor loading associated with that item 
(i.e. the correlation of an item with a factor) has to be > 0.40. [19]
We conducted the vanishing tetrad test (VTT) to examine whether the MGLS conforms to an 
effect indicator model or a causal indicator model. The VTT compares the number of 
vanishing tetrads among items under different assumptions about the items being effect or 
causal indicators. [24] The VTT directly determines whether a possible indicator item 
should be treated as a cause or an effect of the latent construct of interest.
Results
Cohort Characteristics
The total number of observations in the study was 6,261. Mean age of the participants was 
76 years (standard deviation 5.25 years) and 59% of participants were female. This study 
included Caucasian and African American races with 77% and 23%, respectively. Among 
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the participants 23% resided in Forsyth County, North Carolina, 21% in Jackson, 
Mississippi, 29% in Minneapolis, Minnesota and 27% in Washington, Maryland. Among 
participants, 85% had high school or above education and 66% were married. The 
participants took on average 9.4 (standard deviation 5) different medications including 
prescription and over-the-counter medications as well as supplements (Table 2). The most 
commonly taken prescription medications in the sample at Visit 5 were antihypertensive 
drugs (68.5%), drugs for high blood cholesterol (54.2%), blood thinning drugs (29.9%), and 
medications for high blood sugar or diabetes (21.7%).
On the basis of the MGLS, 60.36% of the participants indicated full medication adherence 
while 39.64% reported some level of non-adherence (37.2% intermediate adherence and 
2.43% low adherence). The majority of participants (66.2%) indicated that they took their 
medications 100% of the time during the past four weeks (Table 1).
Measures of reliability
The Spearman inter-item correlation ranged from 0.11 to 0.26 (0.18 on average) that 
indicates a low association among items (Table 3). In the study sample the standardized 
Cronbach’s coefficient alpha for MGLS was 0.47 (Table 4).
Congruent and Factorial Validity
A binary measure of medication non-adherence derived from MGLS and a single-item 
indicating the extent of medication adherence (100% of the time medications were taken in 
the past 4 weeks vs. less than 100%) results in the Spearman correlation of 0.6 (results not 
shown).
Because the MGLS only includes four items, it is difficult to identify more than one factor 
when recommendations suggest three or more items are needed to form a factor. Factor 
analysis of the MGLS suggests one large factor exists accounting for 45% of the total 
variation in the scale. The results of the second exploratory factor analysis, which include 
the MGLS items as well as all other relevant items that assessed medication adherence, are 
presented in Table 5. Based on the Scree Plot presented in Figure 1, a dominant factor exists 
with the possibility of two minor factors. Relevant items (i.e. items with factor loading > 
0.4) for the first factor include “ever forget to take medicines” and “ever careless about 
taking medicines” from the MGLS and “frequency of missed taking medicine” and “percent 
of the time medication was taken” from the other adherence items in the survey. This factor 
reflects the extent of medication adherence but includes forgetfulness, the most prevalent 
reason for non-adherence. The second factor includes two relevant items from MGLS: “stop 
taking medicines when feeling better” and “stop taking medicines if you feel worse”. Two 
relevant items that load on the third factor include “frequency of running out of medicines” 
and “frequency of stretching medications”. A sensitivity analysis where the redundant items 
(Table 1) were included in the factor analysis indicated that the redundant items loaded on 
the same factors as their corresponding items that were kept in the analysis.
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Vanishing Tetrad Test
Running VTT on MGLS results in two non-redundant vanishing tetrads (NRVTs). The 
associated p-value was highly significant (p<0.0001), indicating poor model fit. The finding 
suggests that one or more of the two NRVTs do not vanish as expected assuming the effect 
indicator structure of the model. Therefore, the all effect indicator model assumption for 
MGLS is not consistent with the data.
Discussion
The ARIC cohort provides a large sample of MGLS responses in the elderly population that 
allows for assessment of psychometric properties of MGLS. This analysis can therefore 
inform our understanding of the MGLS as a measure of medication adherence. The MGLS 
has the advantage of being a brief measure of medication adherence that is widely used both 
in research and medical practice capacities. [19]
Numerous studies have reported the internal consistency reliability of the MGLS, showing 
mixed results ranging from low (0.32) to high (0.86) values of Cronbach’s alpha. However, 
the majority of studies including the original MGLS study reported MGLS’ Cronbach’s 
alpha reliability to be below the acceptable value of 0.7 for group level measurement. 
[25,26,27,28,29,30,31,32] Our findings also suggest that the Morisky scale, as currently 
used, lacks consistency when used in an elderly population. In particular, MGLS as a single 
measure of medication adherence did not show an acceptable level of reliability (alpha=0.47, 
compared to 0.7 and 0.9 as the standard level for group- and individual-level measurement) 
[22].
As with the findings of internal consistency estimations of the MGLS, several studies 
examined the dimentioanlity of the scale using principal components analysis. [30] The 
majority of these studies including the original MGLS paper suggested a single factor 
solution, [18,29,33,34] while Toll and colleagues principal component analysis found a two-
factor solution: (1) unintentional nonadherence; (2) purposeful nonadherence” [30] In our 
study, when combined with other items on non-adherence, the MGLS items loaded on 
different meaningful factors. There appears to be a dominant factor that captures extent of 
non-adherence. This factor included the item of frequency of missed medicines and 
forgetting medicines, which is the most prevalent reason for people missing medications; 
thus the forgetting item is correlated with the extent item. More minor factors included 
reasons such as not taking medicines due to health reasons (feeling better or feeling worse) 
and stretching or running out of medication. We also note low correlations among the items 
in MGLS (correlations range from 0.11 to 0.26). In addition, the results of the VTT 
indicated that an effect indicator model for the MGLS in not consistent with the data. Our 
results appear consistent with the findings of Voils et al. 2011, suggesting the need to 
differentiate extent versus reasons for non-adherence. [11]
In 2003, the World Health Organization claimed that improved adherence interventions 
might have far greater impact on population health than any improvement in specific 
medical treatments. [23] Design and delivery of effective adherence interventions require 
valid and reliable information about individuals’ medication-taking behavior across clinical 
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and research settings. [11] Although measures with lower administrative and respondent 
burden are easier to implement and therefore preferred [35] the selected measure should 
reflect the type of information that is required to modify the medication-taking behavior 
(e.g. the extent of or reasons for non-adherence). Many researchers have tried to measure 
self-reported medication non-adherence, which has resulted in several self-report 
instruments. [36] Some measures contain only effect indicators or only causal indicators, 
and some measures such as MGLS contain a combination of effect and causal indicators 
items without being able to identify the unique information provided by each. [11] Given the 
importance and uniqueness of such information, it is imperative for a medication adherence 
self-report instrument to reliably capture both the extent and reasons of non-adherence. To 
our knowledge, the Voils’ scale is the only medication adherence questionnaire that 
purposively measures both extent and reasons for medication adherence. [36]
In 2008, the eight-item Morisky Medication Adherence Scale (MMAS-8) was developed 
from the original four-item MGLS. [37] The MMAS-8 identifies more reasons for 
medication nonadherence and has better internal consistency with Cronbach’s alpha value of 
0.83. [31, 36] Nevertheless, like the MGLS, MMAS-8 has disadvantages such as capturing 
only a few reasons or factors associated with non-adherence, thus providing limited 
information to develop interventions targeting non-adherence. [11,17,31] The MGLS is 
sometimes viewed and used as a screener for nonadherence, where any “yes” response is 
taken as a positive screen for nonadherence. MGLS can be used as a screening and 
monitoring tools to identify those patients who might have medication adherence problems. 
[31]
This study is subject to a few limitations. The sample included only those participants who 
were willing to participate in Visit 5 and responded to the medication adherence questions; 
these participants may be healthier and thus more adherent than the general population. 
Therefore, the full range of medication adherence that is theoretically possible from the 
MGLS may not have been obtained in the ARIC study. In addition, the cross-sectional 
nature of data does not provide the opportunity to assess other measurement properties such 
as test-retest reliability, known group validity and responsiveness of the measure to changes 
in medication adherence over time. The MGLS was asked in ARIC with regard to all 
medications that the cohort participants were taking. Asking about all medications versus 
those for a specific condition may also explain some of the differences in the distribution of 
the reasons for non-adherence seen in this study, which can potentially affect the 
generalizability of the results. Similarly, the exclusion of the redundant and rarely endorsed 
items can limit the generalizability of the results. In addition, the list of reasons for non-
adherence included in the ARIC study medication adherence questionnaire is not 
comprehensive and excludes some of the commonly reported reasons seen in other studies, 
for example, lack of insurance.
Conclusion
This assessment showed that the MGLS lacks consistency when used in an elderly 
population. These findings support the Voils recommendation that medication adherence 
should be conceptualized as both the extent of adherence and reason for adherence. [11] 
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Beyond psychometric reasons, distinguishing between these two factors has clinical 
relevance. The measure of extent provides a metric for distinguishing among different levels 
of medication adherence and allows clinicians and researchers to determine if interventions 
(e.g. pill boxes) may improve extent of adherence. The reasons are descriptive in nature (e.g. 
whether the patient is forgetful, does not like the side effects of treatment, or cannot afford 
the medication) and provide valuable insights into what may cause suboptimal adherence. 
Knowing the extent of and the reasons for non-adherence may help clinicians and 
researchers identify appropriate interventions for the right context.
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Figure 1. 
Scree plot indicating the Eigenvalues after factor analysis of adherence-related questions in 
the survey
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Table 2
Demographic characteristics of the cohort (n=6,261)
Mean (SD) or Percent
Age in years 76 (5)
Sex, male 41%
Education less than high school 15%
Married 66%
ARIC site and race
 Forsyth, Caucasian 21%
 Forsyth, African American 2%
 Jackson, African American 21%
 Minneapolis, Caucasian 29%
 Washington, Caucasian 27%
No. of medications 9.4 (4.9)
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Table 3
The Spearman inter-item correlation matrix of the MGLS
Morisky items Forgetfulness Carelessness Stop when well Stop when worse
Forgetfulness 1.0000
Carelessness 0.2616 1.0000
Stop when well 0.1093 0.2076 1.0000
Stop when worse 0.1068 0.1486 0.2457 1.0000
MGLS: Morisky Green Levine Medication Adherence Scale.
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Table 4
Reliability of MGLS using standardized coefficient alpha (n=6,261)
Item Item-rest correlation* Alpha
Ever forget to take medicines 0.23 0.43
Ever careless about taking medicines 0.31 0.35
Stop taking medicines when feeling better 0.28 0.38
Stop taking medicines if you feel worse 0.25 0.42
Test Scale 0.47
MGLS: Morisky Green Levine Medication Adherence Scale.
*Calculated using the correlation between each item and the overall score of the measure excluding that item.
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Table 5
Polychoric factor analysis of MGLS and other items indicating the extent of adherence (n=6,261)
Questionnaire item Factor1 Factor2 Factor3 Uniqueness
Ever forget to take medicines 0.91* −0.10 −0.02 0.30
Ever careless about taking medicines 0.40* 0.38 −0.02 0.52
Stop taking medicines when feeling better −0.05 0.75* 0.05 0.45
Stop taking medicines if you feel worse −0.05 0.67* 0.01 0.58
Frequency of stretching medicines in past 4 weeks 0.06 0.08 0.62* 0.51
Frequency of running out of medicines in past 4 weeks 0.07 −0.01 0.64* 0.54
Frequency of missed taking of medicines in past 4 weeks 0.84* 0.01 0.10 0.18
Percent of the time medication was taken in past 4 weeks
−0.40* −0.16 0.03 0.75
MGLS: Morisky Green Levine Medication Adherence Scale.
*
Factor loading greater than 0.4.
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